Top

Published in:

01-09-2014 | Review

Peptide YY: more than just an appetite regulator

Authors: Shanta J. Persaud, Gavin A. Bewick

Published in: Diabetologia | Issue 9/2014

Abstract

Replenishment of beta cell mass is a key aim of novel therapeutic interventions for diabetes, and the implementation of new strategies will be aided by understanding the mechanisms employed to regulate beta cell mass under normal physiological conditions. We have recently identified a new role for the gut hormone peptide YY (PYY) and the neuropeptide Y (NPY) receptor systems in the control of beta cell survival. PYY is perhaps best known for its role in regulating appetite and body weight, but its production by islet cells, the presence of NPY receptors on islets and the demonstration that Y1 activation causes proliferation of beta cells and protects them from apoptosis, suggest a role for this peptide in modulating beta cell mass. This review introduces PYY and its potential role in glucose homeostasis, then focuses on evidence supporting the concept that PYY and NPY receptors are exciting new targets for the preservation of beta cells.

Ryan EA, Paty BW, Senior PA et al (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069PubMedCrossRef

Tatemoto K, Mutt V (1980) Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285:417–418PubMedCrossRef

Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed

Grandt D, Schimiczek M, Beglinger C et al (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151–159PubMedCrossRef

Medeiros MD, Turner AJ (1994) Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 134:2088–2094PubMed

Glavas MM, Grayson BE, Allen SE et al (2008) Characterization of brainstem peptide YY (PYY) neurons. J Comp Neurol 506:194–210PubMedCrossRef

Gelegen C, Chandarana K, Choudhury AI et al (2012) Regulation of hindbrain Pyy expression by acute food deprivation, prolonged caloric restriction, and weight loss surgery in mice. Am J Physiol Endocrinol Metab 303:E659–E668PubMedCentralPubMedCrossRef

Upchurch BH, Fung BP, Rindi G, Ronco A, Leiter AB (1996) Peptide YY expression is an early event in colonic endocrine cell differentiation: evidence from normal and transgenic mice. Development 122:1157–1163PubMed

Roth KA, Kim S, Gordon JI (1992) Immunocytochemical studies suggest two pathways for enteroendocrine cell differentiation in the colon. Am J Physiol 263:G174–G180PubMed

10.

Batterham RL, Bloom SR (2003) The gut hormone peptide YY regulates appetite. Ann NY Acad Sci 994:162–168PubMedCrossRef

11.

Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef

12.

Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O’Rahilly S (2003) Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915–919PubMedCrossRef

13.

Chelikani PK, Haver AC, Reidelberger RD (2005) Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146:879–888PubMedCrossRef

14.

Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ (2006) PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291:R367–R375PubMedCrossRef

15.

Ghamari-Langroudi M, Colmers WF, Cone RD (2005) PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab 2:191–199PubMedCrossRef

16.

Baraboi ED, Michel C, Smith P, Thibaudeau K, Ferguson AV, Richard D (2010) Effects of albumin-conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerve. Eur J Neurosci 32:826–839PubMedCrossRef

17.

Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR (1987) Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28:166–170PubMedCentralPubMedCrossRef

18.

Symersky T, Biemond I, Frolich M, Masclee AA (2005) Effect of peptide YY on pancreatico-biliary secretion in humans. Scand J Gastroenterol 40:944–949PubMedCrossRef

19.

La Sala MS, Hurtado MD, Brown AR et al (2013) Modulation of taste responsiveness by the satiation hormone peptide YY. FASEB J 27:5022–5033PubMedCrossRef

20.

Ali-Rachedi A, Varndell IM, Adrian TE et al (1984) Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 80:487–491PubMedCrossRef

21.

Bottcher G, Ahren B, Lundquist I, Sundler F (1989) Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 4:282–288PubMedCrossRef

22.

Bottcher G, Sjoberg J, Ekman R, Hakanson R, Sundler F (1993) Peptide YY in the mammalian pancreas: immunocytochemical localization and immunochemical characterization. Regul Pept 43:115–130PubMedCrossRef

23.

Suzuki A, Nakauchi H, Taniguchi H (2003) Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc Natl Acad Sci U S A 100:5034–5039PubMedCentralPubMedCrossRef

24.

el-Salhy M, Grimelius L, Emson PC, Falkmer S (1987) Polypeptide YY- and neuropeptide Y-immunoreactive cells and nerves in the endocrine and exocrine pancreas of some vertebrates: an onto- and phylogenetic study. Histochem J 19:111–117PubMedCrossRef

25.

Jackerott M, Oster A, Larsson LI (1996) PYY in developing murine islet cells: comparisons to development of islet hormones, NPY, and BrdU incorporation. J Histochem Cytochem 44:809–817PubMedCrossRef

26.

Upchurch BH, Aponte GW, Leiter AB (1994) Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development 120:245–252PubMed

27.

Schonhoff S, Baggio L, Ratineau C et al (2005) Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 25:4189–4199PubMedCentralPubMedCrossRef

28.

Larhammar D (1996) Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65:165–174PubMedCrossRef

29.

Grandt D, Teyssen S, Schimiczek M et al (1992) Novel generation of hormone receptor specificity by amino terminal processing of peptide YY. Biochem Biophys Res Commun 186:1299–1306PubMedCrossRef

30.

Abbott CR, Small CJ, Kennedy AR et al (2005) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043:139–144PubMedCrossRef

31.

Koda S, Date Y, Murakami N et al (2005) The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146:2369–2375PubMedCrossRef

32.

Abbott CR, Monteiro M, Small CJ et al (2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway. Brain Res 1044:127–131PubMedCrossRef

33.

Pellieux C, Sauthier T, Domenighetti A et al (2000) Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A 97:1595–1600PubMedCentralPubMedCrossRef

34.

Yang K, Guan H, Arany E, Hill DJ, Cao X (2008) Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J 22:2452–2464PubMedCrossRef

35.

Mannon PJ, Kanungo A, Mannon RB, Ludwig KA (1999) Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon. Regul Pept 83:11–19PubMedCrossRef

36.

Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ (2013) An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol Ther 139:359–391PubMedCrossRef

37.

Burcelin R, Brunner H, Seydoux J, Thorensa B, Pedrazzini T (2001) Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides 22:421–427PubMedCrossRef

38.

Morgan DG, Kulkarni RN, Hurley JD et al (1998) Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 41:1482–1491PubMedCrossRef

39.

Chandarana K, Gelegen C, Irvine EE et al (2013) Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab 2:142–152PubMedCentralPubMedCrossRef

40.

Sam AH, Gunner DJ, King A et al (2012) Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival. Gastroenterology 143:459–468PubMedCrossRef

41.

Boey D, Lin S, Karl T et al (2006) Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49:1360–1370PubMedCrossRef

42.

Lundquist I, Sundler F, Ahren B, Alumets J, Hakanson R (1979) Somatostatin, pancreatic polypeptide, substance P, and neurotensin: cellular distribution and effects on stimulated insulin secretion in the mouse. Endocrinology 104:832–838PubMedCrossRef

43.

Nieuwenhuizen AG, Karlsson S, Fridolf T, Ahren B (1994) Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. Diabetologia 37:871–878PubMedCrossRef

44.

Ahren B, Larsson H (1996) Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. Eur J Endocrinol 134:362–365PubMedCrossRef

45.

van den Hoek AM, Heijboer AC, Corssmit EP et al (2004) PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53:1949–1952PubMedCrossRef

46.

Liu G, Arnaud-Dabernat S, Kritzik MR, Kayali AG, Zhang YQ, Sarvetnick N (2006) PYY in the expanding pancreatic epithelium. Endocrine 30:103–112PubMedCrossRef

47.

Kahan BW, Jacobson LM, Hullett DA et al (2003) Pancreatic precursors and differentiated islet cell types from murine embryonic stem cells: an in vitro model to study islet differentiation. Diabetes 52:2016–2024PubMedCrossRef

48.

Goldberg Y, Taimor G, Piper HM, Schluter KD (1998) Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Am J Physiol 275:C1207–C1215PubMed

49.

Decressac M, Wright B, David B et al (2011) Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus 21:233–238PubMedCrossRef

50.

Hansel DE, Eipper BA, Ronnett GV (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature 410:940–944PubMedCrossRef

51.

Howell OW, Scharfman HE, Herzog H, Sundstrom LE, Beck-Sickinger A, Gray WP (2003) Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J Neurochem 86:646–659PubMedCrossRef

52.

Nie M, Selbie LA (1998) Neuropeptide Y Y-1 and Y-2 receptor-mediated stimulation of mitogen-activated protein kinase activity. Regul Pept 75–6:207–213CrossRef

53.

Mannon PJ, Mele JM (2000) Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem J 350:655–661PubMedCentralPubMedCrossRef

54.

Mannon PJ (2002) Peptide YY as a growth factor for intestinal epithelium. Peptides 23:383–388PubMedCrossRef

55.

Mannon PJ, Mervin SJ, Sheriff-Carter KD (1994) Characterization of a Y1-preferring NPY/PYY receptor in HT-29 cells. Am J Physiol 267:G901–G907PubMed

56.

Cho YR, Kim CW (2004) Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun 314:773–780PubMedCrossRef

57.

Thiriet N, Deng X, Solinas M et al (2005) Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci 25:5273–5279PubMedCrossRef

58.

Wu YF, Li SB (2005) Neuropeptide Y expression in mouse hippocampus and its role in neuronal excitotoxicity. Acta Pharmacol Sin 26:63–68PubMedCrossRef

59.

Basu A, Sivaprasad U (2007) Protein kinase Cε makes the life and death decision. Cell Signal 19:1633–1642PubMedCentralPubMedCrossRef

60.

Vona-Davis L, McFadden DW (2007) PYY and the pancreas: inhibition of tumor growth and inflammation. Peptides 28:334–338PubMedCrossRef

61.

Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115–2133PubMedCrossRef

62.

Ueberberg S, Ziegler D, Schechinger W et al (2010) In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope. Diabetologia 53:1384–1394PubMedCrossRef

Title: Peptide YY: more than just an appetite regulator
Authors: Shanta J. Persaud
Gavin A. Bewick
Publication date: 01-09-2014
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 9/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-014-3292-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Peptide YY: more than just an appetite regulator

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion

Independent effects of circulating glucose, insulin and NEFA on cardiac triacylglycerol accumulation and myocardial insulin resistance in a swine model

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs. Reply to Holden SE, Bannister CA, Currie CJ [letter]

Fate of abstracts submitted to the 2004 EASD Annual Meeting in Munich

Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial

Effects of calcium–vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page